Ovid Therapeutics Stockholders Approve Key Proposals

Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potentialOvid Therapeutics ( (OVID) ) has issued an announcement. On December 11, 2025, Ovid Therapeutics held a special meeting where stockholders approved three key proposals. The first proposal increased the authorized shares of common stock from 125 million to 315 million. The second proposal allowed the conversion of Series B Preferred Stock and the exercise of Series A and B Warrants, while the third approved the issuance of securities to CEO Jeremy Levin. These approvals are significant for the company’s capital structure and compliance with Nasdaq rules. The most recent analyst rating on (OVID) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Ovid Therapeutics stock, see the OVID Stock Forecast page. Spark’s Take on OVID Stock According to Spark, TipRanks’ AI Analyst, OVID is a Neutral. Ovid Therapeutics’ stock score is primarily influenced by its financial performance challenges, including inconsistent revenue and ongoing losses. However, positive technical indicators and recent corporate events, such as securing significant funding and regaining Nasdaq compliance, provide some optimism. The valuation remains a concern due to negative earnings and lack of dividends. To see Spark’s full report on OVID stock, click here. More about Ovid Therapeutics Ovid Therapeutics Inc. operates in the biotechnology industry, focusing on developing therapies for rare neurological disorders. The company is involved in creating innovative treatments aimed at improving the lives of patients with these conditions. Average Trading Volume: 2,891,277 Technical Sentiment Signal: Buy Current Market Cap: $111.8M Find detailed analytics on OVID stock on TipRanks’ Stock Analysis page.